太溪生技新藥股份有限公司 https://gilvatherap.com Mon, 11 May 2026 08:39:25 +0000 en-US hourly 1 https://wordpress.org/?v=6.7.5 https://gilvatherap.com/wp-content/uploads/2024/11/cropped-LOGO-去背-2-32x32.png 太溪生技新藥股份有限公司 https://gilvatherap.com 32 32 Gilva Therapeutics’GV-100 Phase 1 Clinical Trial Application Approved in Australia https://gilvatherap.com/en/gv100-australia-phase1-approved/ Fri, 08 May 2026 06:33:30 +0000 https://gilvatherap.com/?p=1502 Gilva Therapeutics INC. announces that its lead drug candidate, GV-100, has received approval for its Phase 1 clinical trial application in Australia and will proceed into clinical evaluation in healthy participants. The study is a randomized, double-blind, placebo-controlled Phase 1 clinical trial designed to evaluate the safety, tolerability, and pharmacokinetic profile of GV-100 in healthy […]

The post Gilva Therapeutics’GV-100 Phase 1 Clinical Trial Application Approved in Australia first appeared on 太溪生技新藥股份有限公司.

]]> Gilva Therapeutics INC. announces that its lead drug candidate, GV-100, has received approval for its Phase 1 clinical trial application in Australia and will proceed into clinical evaluation in healthy participants. The study is a randomized, double-blind, placebo-controlled Phase 1 clinical trial designed to evaluate the safety, tolerability, and pharmacokinetic profile of GV-100 in healthy participants. The trial will include single ascending dose, multiple ascending dose, food-effect, and drug-drug interaction evaluations.
GV-100 is an orally available, structurally innovative small-molecule HDAC6 inhibitor developed by Gilva Therapeutics, with a primary focus on autosomal dominant polycystic kidney disease (ADPKD) and other diseases with significant unmet medical needs. ADPKD is one of the most common inherited kidney diseases and may lead to progressive kidney enlargement, declining kidney function, and ultimately end-stage kidney disease. Approval of the Phase 1 clinical trial application in Australia represents an important milestone in the development of GV-100 and marks its transition into clinical-stage development.
Gilva Therapeutics will continue to advance the clinical execution of GV-100 and support its future clinical development in ADPKD and potential global partnership opportunities.

The post Gilva Therapeutics’GV-100 Phase 1 Clinical Trial Application Approved in Australia first appeared on 太溪生技新藥股份有限公司.

]]> Gilva Therapeutics Collaborates with National Taiwan University to Publish First-Generation HDAC6 Inhibitors for ADPKD in the Journal of Medicinal Chemistry https://gilvatherap.com/en/gilva-therapeutics-collaborates-with-national-taiwan-university-to-publish-first-generation-hdac6-inhibitors-for-adpkd-in-the-journal-of-medicinal-chemistry/ Tue, 07 Apr 2026 17:33:11 +0000 https://gilvatherap.com/?p=1483 Gilva Therapeutics announced that its collaborative research with National Taiwan University has been published in the prestigious Journal of Medicinal Chemistry. The study focuses on the design and development of first-generation selective histone deacetylase 6 (HDAC6) inhibitors and their therapeutic potential in autosomal dominant polycystic kidney disease (ADPKD). The findings demonstrate promising activity in disease […]

The post Gilva Therapeutics Collaborates with National Taiwan University to Publish First-Generation HDAC6 Inhibitors for ADPKD in the Journal of Medicinal Chemistry first appeared on 太溪生技新藥股份有限公司.

]]> Gilva Therapeutics announced that its collaborative research with National Taiwan University has been published in the prestigious Journal of Medicinal Chemistry. The study focuses on the design and development of first-generation selective histone deacetylase 6 (HDAC6) inhibitors and their therapeutic potential in autosomal dominant polycystic kidney disease (ADPKD). The findings demonstrate promising activity in disease models, supporting the potential of HDAC6 inhibition as a novel therapeutic approach. This publication highlights Gilva Therapeutics’strength in mechanism-driven small molecule drug discovery and further validates HDAC6 as a key therapeutic target for ADPKD. The company will continue advancing its pipeline toward clinical development.

🔗 Publication link:
https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.5c03139?ref=article_openPDF

The post Gilva Therapeutics Collaborates with National Taiwan University to Publish First-Generation HDAC6 Inhibitors for ADPKD in the Journal of Medicinal Chemistry first appeared on 太溪生技新藥股份有限公司.

]]> 2026/1/12 Forward Asset Management Inc. has resigned as a Board director of Gilva Therapeutics INC., and one replacement director will be appointed to fill the resulting vacancy. https://gilvatherap.com/en/2026-1-12-forward-asset-management-inc-has-resigned-as-a-board-director-of-gilva-therapeutics-inc-and-one-replacement-director-will-be-appointed-to-fill-the-resulting-vacancy/ Wed, 14 Jan 2026 04:00:50 +0000 https://gilvatherap.com/?p=1426 2026/1/12 Forward Asset Management Inc. has resigned as a Board director of Gilva Therapeutics INC., and one replacement director will be appointed to fill the resulting vacancy.

The post 2026/1/12 Forward Asset Management Inc. has resigned as a Board director of Gilva Therapeutics INC., and one replacement director will be appointed to fill the resulting vacancy. first appeared on 太溪生技新藥股份有限公司.

]]> 2026/1/12 Forward Asset Management Inc. has resigned as a Board director of Gilva Therapeutics INC., and one replacement director will be appointed to fill the resulting vacancy.

The post 2026/1/12 Forward Asset Management Inc. has resigned as a Board director of Gilva Therapeutics INC., and one replacement director will be appointed to fill the resulting vacancy. first appeared on 太溪生技新藥股份有限公司.

]]> 2025/4/30 Annual Meeting of Shareholders https://gilvatherap.com/en/%e6%9c%ac%e5%85%ac%e5%8f%b8%e6%96%bc%e6%b0%91%e5%9c%8b114%e5%b9%b44%e6%9c%8830%e6%97%a5%e5%8f%ac%e9%96%8b114%e5%b9%b4%e8%82%a1%e6%9d%b1%e5%b8%b8%e6%9c%83/ Sun, 04 Jan 2026 07:37:31 +0000 https://gilvatherap.com/?p=1342 Vivamus elementum semper nisi. Aenean vulputate eleifend tellus. Aenean leo ligula, porttitor eu, consequat vitae, eleifend ac, enim. Aliquam lorem ante, dapibus in, viverra quis, feugiat a, tellus. Phasellus viverra nulla ut metus varius laoreet. Quisque rutrum. Aenean imperdiet. Etiam ultricies nisi vel augue. Curabitur ullamcorper ultricies nisi.

The post 2025/4/30 Annual Meeting of Shareholders first appeared on 太溪生技新藥股份有限公司.

]]> Vivamus elementum semper nisi. Aenean vulputate eleifend tellus. Aenean leo ligula, porttitor eu, consequat vitae, eleifend ac, enim. Aliquam lorem ante, dapibus in, viverra quis, feugiat a, tellus. Phasellus viverra nulla ut metus varius laoreet. Quisque rutrum. Aenean imperdiet. Etiam ultricies nisi vel augue. Curabitur ullamcorper ultricies nisi.

The post 2025/4/30 Annual Meeting of Shareholders first appeared on 太溪生技新藥股份有限公司.

]]> 2024/12/5 Extraordinary Meeting of Shareholders https://gilvatherap.com/en/113-12-15-extraordinary-meeting-of-shareholders/ Tue, 30 Dec 2025 02:37:22 +0000 https://gilvatherap.morcept.tw/?p=1208 Vivamus elementum semper nisi. Aenean vulputate eleifend tellus. Aenean leo ligula, porttitor eu, consequat vitae, eleifend ac, enim. Aliquam lorem ante, dapibus in, viverra quis, feugiat a, tellus. Phasellus viverra nulla ut metus varius laoreet. Quisque rutrum. Aenean imperdiet. Etiam ultricies nisi vel augue. Curabitur ullamcorper ultricies nisi.

The post 2024/12/5 Extraordinary Meeting of Shareholders first appeared on 太溪生技新藥股份有限公司.

]]> Vivamus elementum semper nisi. Aenean vulputate eleifend tellus. Aenean leo ligula, porttitor eu, consequat vitae, eleifend ac, enim. Aliquam lorem ante, dapibus in, viverra quis, feugiat a, tellus. Phasellus viverra nulla ut metus varius laoreet. Quisque rutrum. Aenean imperdiet. Etiam ultricies nisi vel augue. Curabitur ullamcorper ultricies nisi.

The post 2024/12/5 Extraordinary Meeting of Shareholders first appeared on 太溪生技新藥股份有限公司.

]]> 2023/2/14 Establishment of Gilva Therapeutics, INC. https://gilvatherap.com/en/2023-2-14-establishment-of-gilva-therapeutics-inc/ Wed, 10 Sep 2025 09:30:47 +0000 https://gilvatherap.com/?p=1372 2024/3/20 Extraordinary Meeting of Shareholders https://gilvatherap.com/en/113-3-20-extraordinary-meeting-of-shareholders/ Thu, 19 Dec 2024 08:09:52 +0000 https://gilvatherap.morcept.tw/?p=1159 Vivamus elementum semper nisi. Aenean vulputate eleifend tellus. Aenean leo ligula, porttitor eu, consequat vitae, eleifend ac, enim. Aliquam lorem ante, dapibus in, viverra quis, feugiat a, tellus. Phasellus viverra nulla ut metus varius laoreet. Quisque rutrum. Aenean imperdiet. Etiam ultricies nisi vel augue. Curabitur ullamcorper ultricies nisi.

The post 2024/3/20 Extraordinary Meeting of Shareholders first appeared on 太溪生技新藥股份有限公司.

]]> Vivamus elementum semper nisi. Aenean vulputate eleifend tellus. Aenean leo ligula, porttitor eu, consequat vitae, eleifend ac, enim. Aliquam lorem ante, dapibus in, viverra quis, feugiat a, tellus. Phasellus viverra nulla ut metus varius laoreet. Quisque rutrum. Aenean imperdiet. Etiam ultricies nisi vel augue. Curabitur ullamcorper ultricies nisi.

The post 2024/3/20 Extraordinary Meeting of Shareholders first appeared on 太溪生技新藥股份有限公司.

]]> 2024/6/18 Annual Meeting of Shareholders https://gilvatherap.com/en/113-6-18-annual-meeting-of-shareholders/ Tue, 19 Nov 2024 08:10:37 +0000 https://gilvatherap.morcept.tw/?p=1162 Vivamus elementum semper nisi. Aenean vulputate eleifend tellus. Aenean leo ligula, porttitor eu, consequat vitae, eleifend ac, enim. Aliquam lorem ante, dapibus in, viverra quis, feugiat a, tellus. Phasellus viverra nulla ut metus varius laoreet. Quisque rutrum. Aenean imperdiet. Etiam ultricies nisi vel augue. Curabitur ullamcorper ultricies nisi.

The post 2024/6/18 Annual Meeting of Shareholders first appeared on 太溪生技新藥股份有限公司.

]]> Vivamus elementum semper nisi. Aenean vulputate eleifend tellus. Aenean leo ligula, porttitor eu, consequat vitae, eleifend ac, enim. Aliquam lorem ante, dapibus in, viverra quis, feugiat a, tellus. Phasellus viverra nulla ut metus varius laoreet. Quisque rutrum. Aenean imperdiet. Etiam ultricies nisi vel augue. Curabitur ullamcorper ultricies nisi.

The post 2024/6/18 Annual Meeting of Shareholders first appeared on 太溪生技新藥股份有限公司.

]]>